Production Linked Incentive (PLI) scheme for the Pharmaceutical Sector

Pharma Companies - India
Pharma Companies - India
0 0
Azadi Ka Amrit Mahoutsav

InterServer Web Hosting and VPS
Read Time:4 Minute, 14 Second

Production Linked Incentive (PLI) scheme for the Pharmaceutical Sector

55 manufacturers so far to be benefitted

By PIB Delhi

The PLI Scheme for Pharmaceuticals is based on the strategy of “Atmanirbhar Bharat- Strategies for enhancing India’s manufacturing capabilities and enhancing exports in ten sectors”, which had been approved by the Union Cabinet on 24.02.2021.  The Operational Guidelines for the scheme inviting applications from the pharmaceutical industry were issued on 01.06.2021 by the Department of Pharmaceuticals after intensive consultation with industry and related departments   and NITI Aayog.

The objective of the scheme is to enhance India’s manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high value goods in the pharmaceutical sector. One of the further objectives of the scheme is to create global champions out of India who have the potential to grow in size and scale using cutting edge technology and thereby penetrate the global value chains.

The scheme will provide financial incentives on the incremental sales (over Base Year) of pharmaceutical goods and in-vitro diagnostic medical devices to selected applicants based on pre-defined selection criteria. The incentives will be paid for a maximum period of 6 years for each participant depending upon the threshold investments and sales criteria to be achieved by the applicant. The total quantum of the incentive for the scheme is Rs 15,000 crore. SIDBI is the Project Management Agency for the Scheme.

The applications were invited in three different categories of applicants to ensure fair competition and broad coverage amongst the industry players. The categories were based on the size of the applicant as determined by the global manufacturing revenues from pharmaceutical manufacturing. The scheme has received a very good response from the industry and a total of 278 applications were received by the closing date of 31.08.2021 against which a maximum of 55 applicants were to be selected.

The scheme covers three different product categories for which applicants have applied under the scheme. These products are expected to give an impetus to innovation, R&D and widening of product profile of India Pharmaceutical industry.

  • Category 1: Biopharmaceuticals; Complex generic drugs; Patented drugs or drugs nearing patent expiry; Cell based or gene therapy drugs; Orphan drugs; Special empty capsules like HPMC, Pullulan, enteric etc.; Complex excipients; Phyto-pharmaceuticals.
  • Category 2: Active Pharmaceutical Ingredients / Key Starting materials / Drug Intermediates (except the Active Pharmaceutical Ingredients / Key Starting materials / Drug Intermediates covered under the earlier PLI scheme for APIs/KSMs and DIs being implemented by the Department)
  • Category 3 (Drugs not covered under Category 1 and Category 2): Repurposed drugs; Auto immune drugs, anti-cancer drugs, anti-diabetic drugs, anti-infective drugs, cardiovascular drugs, psychotropic drugs and anti-retroviral drugs; In vitro diagnostic devices; Other drugs not manufactured in India.

The appraisal of the applications has been carried out on the basis of the ranking methodology laid down in the operational guidelines of the Scheme. The selection of applicants in each of the three categories has been approved by the Hon’ble Minister for Chemicals and Fertilizers. The list of the 55 selected applicants is at Annexure-1. The Group A consists of 11 selected applicants, Group-B consists of 9 selected applicants and Group-C consists of 35 selected applicants of which there are 20 MSMEs.

A Technical Committee comprising of experts is assisting the Department with respect to the technical aspects of the scheme. SIDBI has put in place a digital mechanism for business processes being followed under the scheme. A robust monitoring framework will also be put in place to track the progress of the scheme.

With this announcement a major thrust in investment is expected by the pharmaceutical industry which is ultimately aimed at meeting the objectives of the scheme. The detailed scheme guidelines are available on the website of the Department at The portal of SIDBI containing finer details of the scheme can be accessed at


S.NoGroup A: Selected applicants
1Sun Pharmaceutical Industries Limited
2Aurobindo Pharma Limited
3Dr. Reddy’s Laoratories Limited
4Lupin Limited
5Mylan Laboratories Limited
6Cadila Healthcare Limited
7Cipla Limited
8Amneal Pharmaceuticals Private Limited
9Glenmark Pharmaceuticals Limited
10Intas Pharmaceuticals Limited
11Torrent Pharmaceuticals Limited
S.NoGroup B: Selected applicants
1Biocon Limited
2MSN Laboratories Private Limited
3Wockhardt Limited
4Alembic Pharmaceuticals Limited
5Emcure Pharmaceuticals Limited
6Macleods Pharmaceuticals Ltd.
7Biological E Limited
8Natco Pharma Limited
9Strides Pharma Science Limited
S.NoGroup C: Selected applicants
1Vindhya Pharma (India) Private Limited
2Aarti Industries Limited
3Symbiotec Pharmalab Private Limited
4Transasia Bio-Medicals Limited
5Sai Life Sciences Limited
6Poly Medicure Limited
7Concord Biotech Limited
8Amoli Organics Private Limited
9BDR Pharmaceuticals International Private Limited
10Malladi Drugs & Pharmaceuticals Limited
11Symed Labs Limited
12Bal Pharma Limited
13Acme Formulation Private Limited
14Panacea Biotec Limited
15Abhilash Life Sciences LLP
16Neogen Chemicals Limited
17Biophore India Pharmaceuticals Private Limited
18Nosch Labs Private Limited
19Aragen Life Sciences Private Limited
20Sri Krishna Pharmaceuticals Limited
21Optimus Drugs Private Limited
22Venus Remedies Limited
23Psychotropics India Limited
24Steril-Gene Life Sciences Private Limited
25Aurore Life Sciences Private Limited
26Milan Laboratories India Private Limited
27Vandana Life Science Private Limited
28Nitika Pharmaceutical Specialities Private Limited
29Hy-Gro Chemicals Pharmtek Private Limited
30Mendas Pharma Private Limited
31Optimus Pharma Private Limited
32Maiva Pharma Private Limited
33Trivitron Healthcare Private Limited
34Agappe Diagnostics Limited
35Premier Medical Corporation Private Limited

About Post Author

Antara Tripathy

Chief Editor & CEO of IBG NEWS (09/Aug/2018-Present), Secretary of All Indian Reporter's Association,West Bengal State Committee. Earlier Vice President of IBG NEWS (01/Jan/ 2013-08/Aug/2018). She took over the charge from the Founder Editor of the Channel.
0 %
0 %
0 %
0 %
0 %
0 %


IBG NEWS Radio Services

Listen to IBG NEWS Radio Service today.

InterServer Web Hosting and VPS





Please enter your comment!
Please enter your name here